Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect
The overall response rate | Download Table
Frontiers | Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study
Clinical trial end points relevant to patients and society for rare cancers | Semantic Scholar
Starting with higher-dose prednisone boosts 1-year renal response in lupus nephritis
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
Analysis of duration of response in oncology trials. | Semantic Scholar
Objective response rate assessment in oncology: Current situation and future expectations
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Efficacy endpoints in Oncology
Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial
Use of Clinical Trials in Expanding Treatment for Ovarian Cancer - ppt download
Immunotherapy 101 - BioCanRx
Objective response rate assessment in oncology: Current situation and future expectations
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Clinical Trial Endpoints for Oncology Studies
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Response Rate Definition | The Online Advertising Guide
Best Overall Response and Time to Response | Download Table
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
For personal use only
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
Efficacy endpoints in Oncology
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer | NEJM
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
